ERBB2 and small cell carcinoma: Mechanisms of resistance to osimertinib primarily include secondary EGFR mutations (e.g., C797S), MET and erythroblastic oncogene B-2 (ERBB2) amplification, or histological transformation to small cell carcinoma, among others [5].